Clinical Trial Update: Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the immunogenicity and safety of a recombinant CHO cell–derived herpes zoster vaccine in healthy adults aged 30 years a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Recombinant Herpes Zoster Vaccine (CHO Cells) (recombinant herpes zoster vaccine produced in CHO cells)

Snippet

Sponsor: MAXVAX Biotechnology Limited Liability Company | Conditions: Herpes Zoster | Phase 2 | Status: ACTIVE_NOT_RECRUITING